Street View: AbbVie sees strong year ahead, minimizes US tariff concerns

AbbVie ABBV.N raised its full-year profit forecast on Friday while downplaying the potential hit some analysts expect it to take from sector-specific import duties that could be imposed by the Trump administration

Average recommendation of 28 brokerages is "buy", median PT is $210 - data compiled by LSEG

PLAYING WITH A STRONG PIPELINE

J.P.Morgan ("overweight") sees growth potential from newer immunology drugs Skyrizi and Rinvoq, and ABBV has the financial capacity for further business development into the 2030s

"We see ABBV with slightly above average exposure to potential tariffs, given the company's more US-centric sales mix" - JPM

BofA Global Research ("neutral," PO: $200) says ABBV's strength lies in having fewer patent expirations this decade, and continues to observe that consensus under model Skyrizi and Rinvoq, which could be a source of growth

Citigroup ("buy," PT: $210) says co's strong U.S. presence could help mitigate potential near-term pharma tariffs better than expected

Leerink Partners ("outperform", PT: $210) says "Skyrizi's U.S. supply is sourced from domestic manufacturing, and AbbVie's broad global manufacturing footprint could help mitigate the impact of tariffs"